References and Citation Map
Reference List and Citation Map
23 references [1]–[9] core [10]–[16] extended [17]–[20] Paper 5 [21]–[23] Paper 1 autopsy additions
References [1]–[9] form the original core spine. References [10]–[16] address evidential gaps identified across Papers 1–4. References [17]–[20] are additions supporting Paper 5 on PSA kinetics and natural history. References [21]–[23] are additions to Paper 1, updating the autopsy evidence base with the Bell systematic review, the APAC-J national registry analysis, and the Zlotta geographic comparison study. Refs [5] and [6], Johansson and Albertsen, carry weight across both the autopsy/ecology papers and Paper 5; they are listed once in the core spine and their Paper 5 roles are documented in the citation map.
[1] Gatenby RA & Gillies RJ (2008). A microenvironmental model of carcinogenesis. Nature Reviews Cancer, 8(1), 56–61.
Founding paper of evolutionary oncology. Establishes that tumor cells evolve under environmental selection pressures, not mutation alone, and that aggressive phenotypes emerge when ecological conditions favour them. Directly supports the argument that maximal therapeutic suppression accelerates evolutionary escape by restructuring the selection environment.
[2] Zhang J, Cunningham JJ, Brown JS & Gatenby RA (2017). Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nature Communications, 8, Article 1816.
Clinical validation of adaptive therapy in mCRPC. Demonstrates that modulating treatment pressure extends time to progression by maintaining sensitive cell populations as ecological competitors to resistant variants. Uses significantly less total drug over the treatment course. The closest clinical analogue to the Quiet Biology management framework.
[3] Aktipis CA, Boddy AM, Jansen G, et al. (2015). Cancer across the tree of life: cooperation and cheating in multicellularity. Philosophical Transactions of the Royal Society B: Biological Sciences, 370(1673), 20140219.
Frames cancer as the re-emergence of ancestral unicellular behaviour when the governance systems enforcing multicellular cooperation are disrupted. Establishes that maintaining tissue regulatory integrity, metabolic, immune, structural, is itself a form of cancer control. Grounds the QB argument that systemic health is biologically central to cancer management, not merely supportive.
[4] Franks LM (1954). Latent carcinoma of the prostate. Journal of Pathology and Bacteriology, 68(2), 603–616.
Original autopsy discovery demonstrating that microscopic prostate cancer is common in men dying of unrelated causes. Establishes the foundational paradox: tumour initiation is near-universal in older men; clinical progression is not. Anchors the argument that environmental conditions, not genetics alone, determine whether latent cancer becomes lethal. Referenced across Papers 1, 3, 4, and 5.
[5] Johansson JE, Andrén O, Andersson SO, et al. (2004). Natural history of early, localized prostate cancer. JAMA, 291(22), 2713–2719.
Twenty-year outcomes from the Swedish observational cohort: the foundational long-term evidence that most localized prostate cancer progresses slowly, with low disease-specific mortality in well- and moderately-differentiated tumors over the first 10-15 years. Establishes that prostate cancer has a natural biological tempo and that watchful observation is a defensible initial strategy for appropriately selected patients. Provides ecological and natural history grounding in Papers 1, 3, and 4; serves as primary evidential anchor in Paper 5 Section 2.
[6] Albertsen PC, Hanley JA & Fine J (2005). 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA, 293(17), 2095–2101.
Population-level outcome data showing that mortality risk varies dramatically by tumour grade. Gleason 6 disease carries approximately 6% disease-specific mortality at 20 years; Gleason 8-10 exceeds 60-87%. Establishes grade as the primary biological signal for prognosis and reinforces selective intervention over reflex treatment. Competing mortality analysis essential for older patients. Cited in Papers 1, 3, and 4 as natural history support; central to Paper 5 Section 3.
[7] Fidler IJ (2003). The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Reviews Cancer, 3(6), 453–458.
Revisits and formalises Paget's seed-and-soil hypothesis, demonstrating that tumour behaviour depends critically on host microenvironment ('soil') as well as tumour genetics ('seed'). Foundational support for the field control concept and the argument that the tissue environment is an active determinant of tumour fate, not merely a passive substrate.
[8] Vander Heiden MG, Cantley LC & Thompson CB (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science, 324(5930), 1029–1033.
Explains how metabolic context governs tumour growth dynamics, establishing that cancer cells actively rewire metabolism to support proliferation. Supports the concepts of metabolic permissiveness and metabolic constraint. Foundational reference for Paper 2 (Metabolism and Epigenetics).
[9] Hanahan D (2022). Hallmarks of Cancer: New Dimensions. Cancer Discovery, 12(1), 31–46.
Updated hallmarks framework explicitly incorporating non-mutational epigenetic reprogramming, unlocking phenotypic plasticity, and enabling conditions. Frames cancer progression as dependent on system-level conditions, not solely cell-intrinsic mutations. Directly supports the central QB thesis: mutations provide potential; environment determines expression. Referenced in Papers 1, 2, 3, and 4 as the synthesising theoretical anchor.
Evidential gap references incorporated following review of Papers 1-4.
[10] Sakr WA, Haas GP, Cassin BF, Pontes JE & Crissman JD (1993). The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. Journal of Urology, 150(2 Pt 1), 379–385.
Provides the specific age-stratified autopsy prevalence figures cited in Paper 1: histologically identifiable prostate cancer in approximately 30-40% of men in their fifties, rising to more than 60-70% in men over 80. Anchors the quantitative claims that make the autopsy paradox concrete rather than merely descriptive. Also cited in Paper 5 Section 1 to ground the biological prevalence context.
[11] Mosquera JM, Mehra R, Regan MM, et al. (2009). Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clinical Cancer Research, 15(14), 4706–4711.
Documents the prevalence of TMPRSS2-ERG gene fusions in low-grade and incidental tumours, establishing that canonical oncogenic alterations are present in latent prostate cancer. Directly supports the Paper 1 claim that many latent tumours carry molecular features classically associated with malignant potential, yet remain clinically silent.
[12] Kaelin WG & McKnight SL (2013). Influence of metabolism on epigenetics and disease. Science, 339(6122), 1230–1237.
Establishes the mechanistic links between cellular metabolic state and chromatin-modifying enzyme activity, covering acetyl-CoA, SAM, α-ketoglutarate, and NAD⁺ as epigenetic cofactors. Foundational reference for the Paper 2 argument that metabolic reprogramming precipitates epigenetic change rather than merely accompanying it.
[13] Ku SY, Rosario S, Wang Y, et al. (2017). Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science, 355(6320), 78–83.
Experimental model demonstrating that RB1 and TP53 loss cooperate to enable lineage plasticity and neuroendocrine transition under therapeutic pressure. Anchors the Paper 2 claim that epigenetic and transcriptional flexibility is a prerequisite for lineage switching, and that interfering with this flexibility reduces transition probability.
Subsequent evidence has established that RB1 and TP53 loss are necessary but not sufficient for NEPC transition: NEPC tumours have been observed without these mutations, and non-NE CRPC tumours carrying both alterations have been documented without NE phenotype expression. Additional reprogramming factors, including ASCL1 and EZH2-mediated epigenetic remodelling, appear required. The Ku et al. finding remains valid as a foundational mechanistic demonstration; the necessity-without-sufficiency qualification should be noted wherever the claim is made that RB1/TP53 loss drives lineage switching.
[14] Gatenby RA, Silva AS, Gillies RJ & Frieden BR (2009). Adaptive therapy. Cancer Research, 69(11), 4894–4903.
Introduces the formal adaptive therapy framework and the evolutionary double-bind concept. Distinct from the 2008 Nature Reviews Cancer paper [1]; anchors the double-bind discussion in Paper 4 and the ecological management argument in Paper 3.
[15] Kalluri R (2016). The biology and function of fibroblasts in cancer. Nature Reviews Cancer, 16(9), 582–598.
Comprehensive account of normal-to-CAF fibroblast transition and its disproportionate regulatory consequences for epithelial growth, immune exclusion, and extracellular matrix remodelling. Anchors the Paper 3 keystone species argument: stromal loss is ecologically catastrophic for microenvironmental regulation.
[16] West J, You L, Zhang J, et al. (2020). Towards multidrug adaptive therapy. Cancer Research, 80(7), 1578–1589.
Extends adaptive therapy to multidrug protocols and reports on the Moffitt Cancer Center programme including FRAME trial design. Anchors the Paper 4 claim that adaptive therapy is a live and developing clinical programme, not a single historical proof-of-concept.
New references supporting Paper 5: PSA Kinetics and the Natural History of Prostate Cancer.
[17] Wilt TJ, Brawer MK, Jones KM, et al. (PIVOT Study Group) (2012). Radical prostatectomy versus observation for localized prostate cancer. New England Journal of Medicine, 367(3), 203–213.
First large randomized controlled trial comparing radical prostatectomy with observation in clinically localized prostate cancer (n≈700, follow-up to 20 years). Primary finding: surgery did not significantly reduce all-cause or prostate-cancer-specific mortality in the full cohort. Survival benefit confined to higher-risk subgroups. Directly supports the Paper 5 argument that immediate aggressive treatment does not improve outcomes for most men with low-risk localized disease. Randomised confirmation of the Johansson and Albertsen observational findings.
Extended follow-up at median 18.6 years showed a small but borderline-significant all-cause mortality reduction with surgery (HR 0.84; p=0.044), equivalent to approximately one additional life-year gained. The absolute benefit remained modest and was not concentrated in low-risk disease. The Paper 5 argument is unaffected: for low-risk localized prostate cancer, immediate surgery does not deliver survival benefit proportionate to its treatment harms.
[18] Hamdy FC, Donovan JL, Lane JA, et al. (ProtecT Study Group) (2016). 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. New England Journal of Medicine, 375(15), 1415–1424.
Largest randomised trial comparing radical prostatectomy, radiotherapy, and active monitoring in PSA-detected localized prostate cancer (n>1,600, median follow-up 10 years, extended to 15 years in subsequent analysis). Primary finding: prostate cancer-specific mortality approximately 1% and not significantly different across all three groups at 10 years. Monitoring group showed higher metastasis rates at 15 years but without proportionate mortality signal. Provides the most comprehensive comparative harm data: prostatectomy carries significantly higher rates of urinary incontinence and erectile dysfunction across follow-up. Establishes that the survival margin between immediate treatment and active monitoring is narrower than clinical intuition has assumed.
15-year update: Hamdy FC, Donovan JL, Lane JA, et al. (ProtecT Study Group) (2023). Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England Journal of Medicine, 388(17), 1547–1558.
The 2023 update extended median follow-up to 15 years (range 11–21 years) across the same cohort. Prostate cancer-specific mortality remained statistically indistinguishable across all three groups: 17 deaths in active monitoring, 12 in prostatectomy, and 16 in radiotherapy (P=0.53). The absence of survival difference now holds at 15 years, strengthening the Paper 5 argument that the survival margin between immediate treatment and active monitoring is narrower than clinical intuition assumes. The 2023 paper supersedes the 2016 publication as the primary citation where the most current follow-up data is required.
[19] Carter HB, Pearson JD, Metter EJ, et al. (1992). Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA, 267(16), 2215–2220.
Foundational PSA velocity paper using stored serum from the Baltimore Longitudinal Study of Aging. Demonstrates that men who subsequently developed prostate cancer showed significantly higher rates of PSA rise in the years before diagnosis. Establishes PSA velocity (rate of change per year) as a diagnostic and prognostic signal independent of absolute PSA level. Anchors the Paper 5 argument that trajectory encodes biological information that a single measurement cannot provide.
[20] D'Amico AV, Chen MH, Roehl KA & Catalona WJ (2004). Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. New England Journal of Medicine, 351(2), 125–135.
Demonstrates that PSA velocity in the year before diagnosis is an independent predictor of prostate cancer-specific mortality, even after adjusting for grade, stage, and PSA level. Men with pre-diagnosis PSA velocity exceeding 2 ng/mL per year face substantially higher disease-specific mortality regardless of absolute PSA. Directly challenges the clinical habit of making treatment decisions based primarily on PSA level. Anchors the Paper 5 argument that velocity is more prognostically informative than level, and supports PSA doubling time as the primary kinetic monitoring tool in the QB framework.
New references added to Paper 1 following identification of three additional autopsy studies that strengthen the age-prevalence argument, provide national-scale epidemiological quantification, and supply the geographic terrain comparison. These extend but do not replace the existing Paper 1 reference spine.
[21] Bell KJL, Del Mar C, Wright G, Dickinson J & Glasziou P (2015). Prevalence of incidental prostate cancer: a systematic review of autopsy studies. International Journal of Cancer, 137(7), 1749–1757.
The most comprehensive modern synthesis of autopsy prevalence data, pooling 29 separate studies conducted between 1948 and 2013. Reports estimated mean latent prostate cancer prevalence rising from 5% in men under 30 to 59% in men over 79, the largest and most methodologically rigorous confirmation of the age-prevalence curve established by Franks and Sakr. Anchors the Paper 1 Section 2 claim that the age-prevalence relationship is among the most reproducible findings in oncology and has been confirmed across geographically and ethnically diverse populations. Supersedes older multi-country studies as the primary citation for pooled prevalence figures.
[22] Uozaki H, Kikuchi Y, Watanabe M, et al. (2026). Trends in the hidden burden of cancer in an autopsy-based study over 66 years in Japan. JAMA Network Open. DOI: 10.1001/jamanetworkopen.2025.57812.
National-scale analysis of 1,486,557 autopsies registered in the Japanese APAC-J database between 1958 and 2023, the largest longitudinal autopsy dataset in the literature. Key finding for Paper 1: latent prostate cancer was 6.9-fold more frequent than clinical incidence in men aged 75–79, a disparity that persisted across six decades of follow-up. Anchors the Paper 1 Section 2 paragraph quantifying the gap between histological prevalence and clinical incidence at population scale. Companion to Bell [21] and Sakr [10]: Bell establishes the cross-study pooled prevalence curve; Sakr provides the age-bracket figures; this paper provides the clinical-incidence enrichment ratio at national scale.
[23] Zlotta AR, Egawa S, Pushkar D, et al. (2013). Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. Journal of the National Cancer Institute, 105(14), 1050–1058.
Prospective standardised autopsy study comparing latent prostate cancer prevalence in Caucasian men in East Yorkshire, UK, and Japanese men in Tokyo, using identical step-sectioning protocols. Key finding: prevalence and biological features of latent prostate cancer were virtually identical between the two populations, despite dramatically different rates of clinical prostate cancer. Directly supports the Paper 1 Section 7 terrain hypothesis: initiating cellular events occur at similar rates across populations; systemic, metabolic, and environmental conditions determine whether latent clones progress to clinically significant disease. The most powerful geographic evidence for the seed-and-soil / terrain framework in the QB series.
All 23 references mapped across the five papers by section and claim. Refs [5] and [6] are core references with primary analytical weight in Paper 5; they appear in both the Papers 1–4 and Paper 5 sections of the map.
[5] Johansson and [6] Albertsen appear in Papers 1, 3, 4, and 5, they are the empirical spine of the series. Their primary analytical home is Paper 5, where they are examined at length; in Papers 1, 3, and 4 they provide natural history context and ecological grounding.
[9] Hanahan appears in Papers 1, 2, 3, and 4 as the synthesising theoretical anchor, providing the updated hallmarks framework that unifies the series' ecological argument.
[4] Franks appears in Papers 1, 3, 4, and 5 as the foundational paradox, the autopsy observation from which the entire ecological argument originates.
[1] Gatenby (Nature Reviews Cancer 2008) and [14] Gatenby (Cancer Research 2009) are distinct papers cited for distinct purposes: [1] for the ecological model of carcinogenesis; [14] for the formal adaptive therapy framework. They should not be conflated.
[21] Bell, [22] APAC-J, and [23] Zlotta form a three-part autopsy evidence update for Paper 1: Bell provides the pooled cross-study prevalence curve; APAC-J provides the national-scale clinical-incidence enrichment ratio; Zlotta provides the geographic terrain comparison. Together they update and extend the Paper 1 autopsy argument without replacing Franks [4] or Sakr [10].